User:NMRDNP/sandbox

Nemaura Medical Inc. is a medical technology company developing sugarBEAT® as a non-invasive glucose monitoring adhesive skin-patch for adjunctive use by persons with diabetes[1].

History
The proprietary technology used in sugarBEAT® was initially developed as a non-invasive transdermal drug delivery platform by Nemaura Pharma, and subsequently reconfigured into a non-invasive diagnostic medical technology and spun out into Nemaura Medical in 2013[2].

SugarBEAT® was initially  developed as a wrist worn device which underwent European clinical studies and received CE approval in February 2016, allowing European product launch. Nemaura subsequently decided not to market the wrist worn version of sugarBEAT® and instead conducted further development to convert to the current format[3].

SugarBEAT®
SugarBEAT® is a non-invasive blood glucose monitor based on Nemaura’s patented BEAT™ platform technology[4 ]. SugarBEAT combines a daily-disposable adhesive skin patch with a Bluetooth-enabled rechargeable transmitter that transmits glucose readings every five minutes to an app on a user’s smart device.

SugarBEAT® works by non-invasively extracting interstitial fluid from below the skin through a membrane into the adhesive skin-patch, where the  transmitter measures then wirelessly transmits glucose data to the smart device application. A proprietary algorithm then converts the data to a concentration value displayed on the user’s smart device. Each daily disposable adhesive skin-patch requires calibration via a finger prick glucose measurement when first applied to the skin[5).

Nemaura completed European clinical trials of sugarBEAT in the fourth quarter of 2017[6] and expects to receive CE Marking in 2018, followed by a European commercial launch initially in the United Kingdom focusing both on insulin-dependent and non insulin-dependent diabetics. The Company also plans to initiate a U.S. clinical study for potential FDA clearance of sugarBEAT in 2018.

In 2015, Nemaura signed a joint venture agreement with Dallas Burston Ethitronix (DBJ Jersey) to market the sugarBEAT system in Europe[7 ]. DBJ Jersey was founded by Dr. Dallas Burston (MBBS), a pharmaceutical entrepreneur who has founded and built companies including Bartholomew-Rhodes, Ashbourne Pharmaceuticals, Dallas Burston Ltd and DB Ashbourne LDT[8].